Readouts
readoutreadoutreadoutreadout
Tirzepatide SURPASS-2 delivers superior HbA1c and weight reductions vs semaglutide 1 mg
Clinical trial registry and NEJM publication
Aug 5, 2021
Semaglutide 2.4 mg achieves 14.9% mean weight loss in STEP 1
Clinical trial registry and NEJM publication
Mar 18, 2021
Retatrutide phase 2 shows up to 24.2% mean weight loss at 48 weeks
Clinical trial registry and conference presentation
Jun 26, 2023
AMG 133 phase 1 demonstrates up to 14.5% weight loss after 12 weeks
ClinicalTrials.gov record and conference abstract
Dec 8, 2022